Early Clinical Efficacy And Safety Of Loplatin Combined With Paclitaxel In Treatment Of Advanced Epithelial Ovarian Cancer

Objective: To investigate early clinical efficacy and safety of loplatin combined with paclitaxel(TL)in the treatment of advanced epithelial ovarian cancer.Methods: Choosed between July 2017 and November 2019 Zunyi Medical Universty Affiliated Hospital of department of gynaecology hospital parallel with tumor cells to destroy the loss ? A ~ ? C stage epithelial ovarian cancer patients 99 cases,postoperative chemotherapy regimens according to different divided into TL(paclitaxe;lobaplatin),TP(paclitaxe;carbopla)and TC(paclitaxe;cisplatin)group,each group of 37 cases respectively,29 cases,33 cases.After the first 3 period of treatment,use whole abdominal CT scan + enhanced residual tumor size measurement and monitoring of patients in each group serum CAl25 change in the evaluation of three groups of patients with early clinical curative effect,according to the national cancer institute common adverse event evaluation standard set by the evaluation of drug side effects,according to the function of ovarian cancer treatment system to evaluate the quality of life.Results:1.Early clinical efficacy: the effective rates of TL,TP and TC groups were 78.4%,72.3%and 75.8%,and the disease control rates were 94.5%,86.2% and 93.9%,respectively.There was no significant difference in the effective rate and disease control rate among the three groups(P> 0.05).2.Changes in the level of CA125:three groups of patients after each chemotherapy CA125 levels were significantly decreased(P< 0.05),although three groups of patients with general trends there was no significant difference(P> 0.05),but the TL and TC group was at the end of the second course of serum CA125 had returned to normal level,overcast rate were significantly higher than TP group(P<0.05),but no obvious difference TL and TC group(P>0.05).3.Comparison of adverse reactions: The incidence and severity of gastrointestinal adverse reactions in the TL group were significantly lower than those in the TP and TC groups (P<0.01).Among the adverse reactions of the blood system,the three groups had no difference in the incidence and severity of white blood cell and hemoglobin reduction(P>0.05);the incidence and severity of platelet reduction in the TC group was significantly higher than that in the TP group(P<0.05),while the TL group was no significant difference between the TP and TC groups(P>0.05).The three groups had no significant difference in the incidence and severity of liver function impairment(P>0.05).All patients had no renal impairment.4.Quality of life score: There had no significant difference in the total score of quality of life in the three groups before chemotherapy(P> 0.05),The quality of life of the three groups was improved after chemotherapy,but the total score of quality of life in the TL group after chemotherapy was higher than that in the TP and TC groups,and there was a significant difference with the TP group(P< 0.05),but no significant difference with the TC group(P> 0.05).Conclusion: The treatment of advanced epithelial ovarian cancer with satisfactory tumor cell depletion after application of the three regimens has the same therapeutic effect,but the TL regimen has a lighter gastrointestinal reaction and higher safety,which is worthy of clinical promotion.